Reactions Weekly

, Volume 1635, Issue 1, pp 84–84 | Cite as

Cisplatin/pemetrexed

Fatigue and ototoxicity: case report
Case report
  • 24 Downloads
Author Information

An event is serious (FDA MedWatch definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * requires intervention to prevent permanent impairment or damage

A 56-year-old man developed fatigue and ototoxicity following the administration of cisplatin and pemetrexed [routes not stated].

The man, who had been diagnosed with malignant pleural mesothelioma, was started on chemotherapy with cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 on 14 November 2014. After the first cycle, he experienced mild fatigue. He received total 6 cycles of cisplatin and pemetrexed. Later, he received only pemetrexed from the seventh cycle. After the seventh cycle, he developed self-limiting ototoxicity that leads dose reduction in the eighth and ninth cycle. Afterward, his chemotherapy was changed to carboplatin and pemetrexed. At follow-up, fourteen months after the diagnosis, he was continued on chemotherapy [outcomes not stated].

Author comment: "The observed toxicities were mild fatigue after the first cycle and self-limiting ototoxicity after 7 cycles."

Reference

  1. Branchi F, et al. A case of pseudoachalasia hiding a malignant pleural mesothelioma. Tumori 102 (Suppl. 2): S50-S53, Nov 2016. Available from: URL: http://doi.org/10.5301/tj.5000521 - ItalyCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Personalised recommendations